April 1, 2022

Novocure to Report First Quarter 2022 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three months ended… Read More
learn more
March 24, 2022

Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial

Patients in phase 2 pilot trial 2-THE-TOP had median progression-free survival of 12.1 months compared with 7.9 months for matched-control patients from EF-14 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight Brain Institute at the… Read More
learn more
March 23, 2022

Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer

Pre-specified interim analysis concluded that the INNOVATE-3 study should proceed to final analysis as planned ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 pivotal INNOVATE-3 study evaluating the safety and efficacy of Tumor Treating Fields (TTFields) together… Read More
learn more
February 28, 2022

Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation

Professor Palti is the inventor of Tumor Treating Fields, electric fields that disrupt cancer cell division The Israel Prize is regarded as the State of Israel’s highest cultural honor ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Yoram Palti, Novocure’s Founder and Chief Technology Officer, has… Read More
learn more
February 24, 2022

Novocure’s General Counsel Resigns After 10 Years of Service

Todd Longsworth’s work was foundational to the growth of Novocure in becoming a global oncology company Barak Ben Arye has been appointed to General Counsel, effective April 1 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that Todd Longsworth, General Counsel, has resigned. Mr. Longsworth’s last day… Read More
learn more
February 24, 2022

New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response

Tumor Treating Fields dually activates the STING and AIM2 pro-inflammatory signaling pathways that drive early anti-tumor immune responses ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption… Read More
learn more
February 24, 2022

Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

Full year 2021 net revenues of $535 million, an increase of 8% year-over-year Invested record $201 million in 2021 in research and development initiatives intended to advance Tumor Treating Fields science and technology ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter… Read More
learn more
January 10, 2022

Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update

Preliminary full year 2021 net revenues of $535 million and fourth quarter net revenues of $133 million DMC interim analysis for INNOVATE-3 pivotal trial in ovarian cancer anticipated in early Q2 2022 given limited total number of events to date in fast-recruiting trial Novocure to present at… Read More
learn more
January 4, 2022

Novocure to Participate in the 40th Annual J.P. Morgan Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today it will participate in the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10 through January 13, 2022. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. EST on… Read More
learn more